PTN — Palatin Technologies Share News
0.000.00%
Last trade - 00:00- $9.10m
- $1.61m
- $13.19m
Brief: Palatin Receives Notice Of Non-Compliance From NYSE American
Brief: FDA Confirms Acceptability Of Palatin's Remaining Phase 3 Pivotal Clinical Trials
Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Administered With A Pde5i For The Treatment Of Erectile Dysfunction
Palatin rises as mid-stage study of obesity treatment begins
Brief: Palatin Initiates Phase 2 Clinical Study Of Bremelanotide For The Treatment Of Obesity
Brief: Palatin Technologies Phase 2 Clinical Study Expected To Begin Mid-Calendar Year 2024
Brief: Palatin To Present Dry Eye Disease Clinical Data Results
Palatin slumps as dry-eye drug fails to meet one of the main goals in study
Brief: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease
Brief: Palatin Reports Q2 Fiscal Year 2024 Financial Results
Brief: Palatin Provides Corporate Update And Highlights Strategic Priorities For Calendar Year 2024
Brief: Palatin Completes Sale Of Vyleesi® To Cosette Pharmaceuticals For Up To $171 Million
Brief: Palatin Gets NYSE Notice Accepting The Listing Standards Compliance Plan
Brief: Palatin Announces Closing Of $5 Mln Registered Direct Offering
Brief: Palatin Announces $5 Million Registered Direct Offering
Brief: Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss
Brief: Palatin Receives Notice Of Non-Compliance From NYSE American
Brief: Palatin Completes Enrollment In Phase 3 Melody-1 Study Of Pl9643 For The Treatment Of Patients With Dry Eye Disease